New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection by Revest, Matthieu et al.
New in vitro and in vivo models to evaluate antibiotic
efficacy in Staphylococcus aureus prosthetic vascular
graft infection
Matthieu Revest, C. Jacqueline, R. Boudjemaa, J. Caillon, V. Le Mabecque,
A. Breteche, K. Steenkeste, Pierre Tattevin, G. Potel, Christian Michelet, et
al.
To cite this version:
Matthieu Revest, C. Jacqueline, R. Boudjemaa, J. Caillon, V. Le Mabecque, et al.. New in
vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic
vascular graft infection. Journal of Antimicrobial Chemotherapy, 2016, 71 (5), pp.1291-1299.
<10.1093/jac/dkv496>. <hal-01274236>
HAL Id: hal-01274236
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01274236
Submitted on 22 Mar 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Title page 
 
New in vitro and in vivo Models to evaluate Antibiotic Efficacy in Staphylococcus aureus 
Prosthetic Vascular Graft Infection 
 
M. Revest1,2,3, C. Jacqueline1, R. Boudjemaa4, J. Caillon1, V. Le Mabecque1, A. Breteche1, K. 
Steenkeste4, P. Tattevin2,3, G. Potel1, C. Michelet2,3, MP. Fontaine-Aupart4, D. Boutoille1,5 
 
 
1 Université Nantes, Faculté Médecine EA3826 Nantes, France 
2 CHU Rennes Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, 35033 
Rennes Cedex, France  
3 CIC Inserm 1414, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes Cedex, France 
4 Institut des Sciences Moléculaires Orsay, CNRS, Université Paris-Sud, 91405 Orsay, France 
5 CHU Nantes, Infectious Diseases Unit, Hôtel Dieu, Nantes, France 
 
Corresponding author: 
Dr Matthieu Revest, 
CHU Rennes Infectious Diseases and Intensive Care Unit, Pontchaillou Hospital, 35033 
Rennes Cedex, France  
Phone: +33 2 99 28 37 98 
Fax: +33 2 99 28 94 64 
matthieu.revest@chu-rennes.fr 
 
Running title: evaluation of different antibiotics for vascular prosthesis infections treatment 
 
Key words: Staphylococcus aureus, animal models, biofilm, surgical infection, vascular 
prosthesis infections  
Abstract: 
 
Objective. Prosthetic vascular graft infection (PVGI) is an emerging disease, mostly due to 
staphylococci, with limited data regarding efficacy of current antistaphylococcal agents. We 
aimed to assess the efficacy of different antibiotic regimens. Methods. Six different strains of 
methicillin-susceptible (MSSA) and methicillin-resistant S. aureus (MRSA) were used. We 
compared results of minimal biofilm inhibitory and eradicating concentrations (MBICs and 
MBECs) obtained with a Calgary Biofilm Pin lid Device (CBPD) to those yielded by an 
original Dacron®-related minimal inhibitory and eradicating concentrations measure model. 
We then used an original murine model of Staphylococcus aureus vascular material infection 
to evaluate efficacy of different antibiotic regimens: vancomycin and daptomycin combined 
or not with rifampicin for MRSA and same groups with cloxacillin and cloxacillin associated 
with rifampicin for MSSA. Results. We demonstrated that classical measures of MBICs and 
MBECs with CPBD could overestimate the decrease of antibiotic susceptibility in material-
related infections and that the nature of the support used might influence the measure of 
biofilm susceptibility since results yielded by our Dacron®-related minimal eradicating assay 
were lower than those found on a plastic device. In our in vivo model, we showed that 
daptomycin was significantly more bactericidal than comparators for some strains of MRSA 
or MSSA but not for all. For the majority of strains, it was as efficient as comparators. The 
addition of rifampicin to daptomycin did not enhance daptomycin efficacy. Conclusions. 
Despite the heterogeneity of results according to bacterial strains, these innovative models 
represent an option to better evaluate in vitro efficacy of antibiotics on Dacron®-related 
biofilm S. aureus infections, and to screen different antibiotic regimens in a mouse-model of 
PVGIs.  
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Introduction 
More than 400 000 vascular grafts are inserted annually in the United States1 and 
approximately 50 000 in France.2 Prosthetic vascular graft infections (PVGIs) are among the 
most serious complications associated with these procedures,1 with 30 day- and one year-
mortality rates of, respectively, 10–25%, and 50%.3 Staphylococcus aureus is the main 
pathogen, and methicillin resistant S. aureus (MRSA) accounts for almost 50% of S. aureus 
PVGIs in North America.4 Clinical data regarding the optimal antibiotic therapy for these 
infections are scarce, in the absence of any comparative clinical trial dealing with the 
treatment of PVGIs.5 Hence, experimental data are needed to better identify the optimal 
antibiotic regimens for PVGIs.  
Biofilm developed onto the vascular prosthesis plays a significant role in the difficulties 
encountered for treating PVGIs. Firstly, biofilm acts as a mechanical barrier against antibiotic 
penetration. Secondly, bacteria embedded in a mature biofilm enter into an altered metabolic 
state associated with a dramatic decrease of susceptibility to most antibiotics.6, 7 Many studies 
showed that minimal biofilm inhibitory concentrations (MBIC) and minimal biofilm 
eradicating concentrations (MBEC) of antibiotics are much higher than their respective 
minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC), as 
measured on planktonic bacteria.8-10 However, most studies evaluated antibiotic efficacy on 
artificial materials not used in clinical practice, although the nature of the material may 
influence these results. In addition, although helpful, in vitro data may fail to capture what 
happens in vivo. Animal models of PVGIs have mainly been used to evaluate techniques to 
prevent PVGIs,11-14 but no animal model assessing the efficacy of antibiotics on infection of 
the Dacron® vascular prosthesis used in clinical daily practice has been described so far. 
In this study, we investigated the activities of cloxacillin, vancomycin, daptomycin and 
rifampicin against different strains of methicillin-susceptible S. aureus (MSSA) and MRSA in 
vitro. Those activities were determined against planktonic bacteria (MIC and MBC), and 
against adherent bacteria (MBIC and MBEC). To evaluate whether the nature of the support 
influences results for MBIC and MBEC, two different techniques were used: a largely used 
modified version of the Calgary Biofilm Pin Lid Device (CBPD) and an original model of 
Dacron®-related biofilm. Then, cloxacillin, vancomycin, daptomycin whether or not 
combined with rifampicin, were evaluated in a new mouse vascular-material infection model, 
using the same strains of S. aureus. 
 
Materials and methods 
Bacterial strains 
Six different strains of S. aureus were used for all experiments.  For MSSA: two different 
clinical strains, thereafter named 171 and 176, isolated from patients with S. aureus 
bloodstream infections, and one strain from the American Type Culture Collection: ATCC 
27217. For MRSA: two different strains, thereafter named BCB8 and 117, also isolated from 
blood cultures, and one ATCC strain: ATCC 33591. Bacteria were stored in a cryovial bead 
preservation system at -80°C. 
 
Antimicrobial agents 
Clinical forms of the following antibiotics were used: cloxacillin (Astellas Pharma, Levallois-
Perret, France) stored in a 100 mg/mL stock-solution, vancomycin (Sandoz, Levallois-Perret, 
France) stored in a 50 mg/mL stock-solution, daptomycin (Novartis Pharma SAS, Rueil-
Malmaison, France) stored in a 50 mg/mL stock-solution and rifampicin (Sanofi-Aventis, 
Paris, France) stored in a 60 mg/mL stock-solution. All the stock-solutions were prepared in 
sterile and pyrogen-free 0.9% saline except for rifampicin, which was prepared in sterile 
water, and stored at -80°C before utilization. 
 
In vitro experiments 
All the following experiments were performed at least in duplicate, with all the 
staphylococcal strains evaluated. Biofilm formation was compared between polystyrene 
(CPBD) and Dacron® using confocal microscopy.  
MICs and MBCs 
The MICs and the MBCs values for cloxacillin, vancomycin, daptomycin and rifampicin were 
determined by the broth macrodilution method in cation-adjusted Mueller-Hinton broth 
(CAMHB), according to the European Committee on Antimicrobial Susceptibility Testing 
(EUCAST). Media were supplemented with 50 mg/L Ca2+ for daptomycin.  
MBICs and MBECs 
A modified Calgary device was used as previously described.8, 15 Briefly, biofilm was formed 
by immersing pegs of a modified microtiter lid into wells of a flat-bottom 96-well microtiter 
plate. Each well was filled with 150 μL of a 3 McFarland S. aureus broth medium solution. 
After a 24-h incubation at 37°C, pegs lids were rinsed 3 times in sterile water, placed onto 
flat-bottom microtiter plates containing antibiotic twofold dilutions in 150 μL of CAMHB per 
well, and incubated for 24 h at 37°C. The MBIC were defined as the minimal concentration of 
antibiotic inhibiting bacterial growth, as determined by reading turbidity of media at 650 nm. 
Pegs with no bacterial growth were again rinsed 3 times with sterile water and sonicated 
(Aquasonic sonicator, 35 kHz for 5 minutes) followed by vortexing for 30 seconds to remove 
biofilm from the support. A new cover plate was added and this new device was cultured for 
24 h at 37°C in CAMHB. The MBEC was defined as the minimal concentration of antibiotic 
where no bacterial growth was documented.  
Dacron®-related minimal biofilm inhibitory concentrations (dMBICs) and the Dacron®-
related minimal biofilm eradicating concentrations (dMBECs) 
Commercially available woven Dacron® grafts (CardialTM, Bard, Saint-Etienne, France) were 
cut into 1 cm x 1 cm squares and sterilized. To cover the biomaterial with proteins and thus to 
facilitate the bacterial graft, these Dacron® sheets were incubated at 37°C under sterile 
conditions with horse serum for 24 h. They were rinsed 3 times with sterile water to remove 
the horse serum and then incubated for 24 h at 37°C with 1 mL per patch of Mueller-Hinton 
broth (MHB) containing 108 colony forming units (CFU)/mL of S. aureus. Again, they were 
rinsed 3 times in sterile water to eliminate the planktonic bacteria, dried with a sterile gauze 
compress, and plunged into tubes filled with CAMHB containing none (control groups) or 
serial antibiotic dilutions, and incubated for 24 h at 37°C. dMBIC for each antibiotic and 
strain couple was defined as the antibiotic concentration of the first tube with no visible 
bacterial growth. Then, Dacron® patches with no bacterial growth were removed from their 
tubes, rinsed 3 times in sterile water, dried with a sterile gauze compress and plunged again in 
MHB. A sonication (35kHz for 5 minutes) was performed followed by vortexing for 30 
seconds. These MHB containing the Dacron® sheets were incubated for 24 h at 37°C. 
dMBECs were defined as the antibiotic concentration of the first tube with no bacterial 
growth. 
Confocal microscopy evaluating biofilm formation depending on the support 
Twenty-four h-biofilms prepared as previously described were observed using a Leica TCS 
SP5 confocal laser-scanning microscope (Leica Microsystems, France). Bacteria were stained 
with 2.5 µM Syto9® (Invitrogen), which is able to penetrate all bacteria, and 5 µL of 1-
mg/mL propidium iodide (PI, Invitrogen), which can only penetrate dead cells. Syto9® and PI 
were excited at 488 nm and 543 nm, respectively, and their fluorescence emissions were 
collected between 500 and 600 nm for Syto9® and between 640 and 750 nm for PI. Images 
were acquired using a 63x with a 1.4 numerical aperture oil immersion objective. The size of 
the confocal images was 512 x 512 pixels (82 x 82 µm²), recorded with a z-step of 1 µm and a 
3x zoom. For each biofilm, at least four different regions were analysed.  
 
In vivo experiments 
All experiments were approved by the French ministry of research and the regional 
committee of animal ethics and animals were cared for in line with national guidelines. 
Animals 
Four-weeks old female Swiss mice (RjOrl/SWISS, Janvier laboratory St Berthevin, France) 
weighing approximately 20 g were maintained on a 12-h light/dark cycle with free access to 
food and water. Eight to 15 animals per group were used for analysis.  
Biomaterial 
Sterile 1 cm2 squares of commercially used Dacron® were incubated with sterile serum of 
healthy female Swiss mice during 24 h at 37°C. Then, they were implanted into mice.  
Surgical procedures 
Mice were anesthetized with ketamine (70 mg/kg) and Xylazine (10 mg/kg) through 
intraperitoneal (IP) injection. Under sterile conditions, a 10-mm horizontal incision in the 
center of the back was made to create a subcutaneous pocket. A sterile Dacron® patch was 
implanted into this pocket. Skin was closed with sutures (Vicryl 5/0). Two days after Dacron® 
implantation, a saline solution (0.2 mL) containing 107 CFU of S. aureus was 
transcutaneously inoculated onto the graft surface. During inoculation, mice were 
anesthetized with isoflurane (0.8 L/min, 3%).  
Antimicrobial treatment regimens 
All the antibiotics used were administered at dose regimens resulting in serum concentrations 
similar to those obtained in humans. Mice were randomized into 14 groups. For MRSA: no 
treatment (controls); vancomycin group (subcutaneous injection (SC), 110 mg/kg/12 h);16 
daptomycin group (50 mg/kg/24 h, SC);17 Rifampicin group (30 mg/kg/12 h, IP);18 
vancomycin-rifampicin group; daptomycin-rifampicin group; for MSSA: same groups + 
cloxacillin group (200 mg/kg/12 h, SC)19 and cloxacillin-rifampicin group. Vancomycin and 
cloxacillin solutions were prepared in sterile 0.9% saline, daptomycin in sterile Ringer-
Lactate and rifampicin in sterile 5% glucose serum. Mice were treated for 48 h and then 
euthanized following international guidelines.  
Bacterial counts 
Dacron® patches were removed under aseptic conditions, homogenized in 0.5 mL of saline 
buffer and vortexed during 30 seconds. Fifty microliters of this solution were used for 
quantitative bacterial cultures. The Dacron® patches were then sonicated (35kHz for 5 
minutes) and 50 µL of the supernatant was inoculated for cultures on Tryptic Soy (TS) and 
Chapman agar plates, incubated at 37°C. The bacterial count was performed after 48 h of 
incubation. Spleens were also homogenized in 1 mL of saline buffer for bacterial cultures. 
Animals for which the spleen bacterial cultures were positive were considered to be 
bacteriemic. In case of a positive bacterial culture, in vitro drug susceptibility testings were 
performed using the Vitek 2 automated identification and susceptibility testing system with 
the Advanced Expert System (bioMerieux, Lyon, France), and interpreted according to the 
EUCAST criteria. 
Statistical analysis 
GraphPad prism software (version 6.0; GraphPad Software, San Diego, CA, USA) was used. 
Normally distributed data were analyzed using analysis of variance to compare the effects 
between the different groups, followed by a Bonferroni’s test to compare the groups two by 
two. P < 0.05 was considered to be statistically significant. 
 
Results 
In vitro efficacy of antibiotics in biofilms are influenced by the nature of the support 
Confocal microscopy confirmed a biofilm formation for all strains on polystyrene (Figure 1a), 
or Dacron® (Figure 1b). However, biofilms formed on Dacron® sheets were less dense and 
thick as compared to those found with the modified CPBD.  
MBIC and MBEC measures demonstrated a dramatic reduction of bacterial susceptibilities to 
all antibiotics tested, for all strains. dMBICs and dMBECs were also higher than MICs and 
MBCs for all strains tested. However, decreases of susceptibilities were less pronounced on 
Dacron® than on polystyrene, with the modified Calgary device (Table 1): for all the 
conditions evaluated, MBECs were much higher than dMBECs. 
 
Daptomycin efficacy on MRSA vascular material infection is superior to comparators 
for one strain but not for others 
There was no difference between bacterial cultures before and after Dacron® sonication. For 
MRSA BCB8, daptomycin was significantly more bactericidal than vancomycin with a 
dramatic reduction of bacterial load after a 48 h-treatment (- 5.85 log10 CFU/cm
2 as compared 
to the control group, P < 0.001, and - 3.47 log10 CFU/cm
2 as compared to vancomycin, P < 
0.001), whether or not combined with rifampicin. The bactericidal activity of vancomycin 
was significantly improved when combined with rifampicin, although this combination 
remained less bactericidal than daptomycin alone on this isolate (P < 0.001). Rifampicin 
monotherapy demonstrated good efficacy (- 4.5 log10 CFU/cm
2 vs control group, P < 0.001) 
(Figure 2). No emergence of antibiotic resistance was observed on bacteria recovered from 
positive cultures. 
For MRSA 117 and 33591, results were strikingly different. For both strains, there were no 
significant differences between daptomycin, vancomycin and rifampicin monotherapies. 
Combined therapies demonstrated no significant benefit as compared to monotherapies 
(Figure 2). Although not statistically significant, there was a trend towards higher efficacy of 
vancomycin-rifampicin as compared to daptomycin-rifampicin. Once again, no antibiotic 
resistance was documented after treatment for both strains. 
Spleen cultures were more frequently positive for controls than for therapeutic groups. There 
was no significant difference between therapeutic groups.   
 
Daptomycin efficacy on MSSA vascular material infection depends also on bacterial 
strains 
As for MRSA, bacterial cultures after sonication did not differ from those without sonication. 
Daptomycin was significantly more bactericidal than cloxacillin for MSSA 176 (– 1.27 log10 
CFU/cm2 (CI 95%: 0.32 to 2.22), P <  0.05), but not for MSSA 27217 and MSSA 171 (Figure 
3). A trend towards better efficacy of daptomycin vs vancomycin on MSSA 176 (- 1.1 log10 
CFU/cm2; CI 95%: -0.16 to 2.37) was observed. Daptomycin and cloxacillin demonstrated 
higher efficacy than vancomycin for MSSA 171 (respectively – 2.72 log10 CFU/cm2 (CI 95%: 
0.75 to 3.79) and – 2.1 log10 CFU/cm2 (CI 95%: 0.55 to 3.65); P < 0.001 for both). 
Combination of cloxacillin, vancomycin, or daptomycin, with rifampicin was more 
bactericidal than monotherapies for the 27217 strain. This effect was less pronounced for 171 
and 176. Surprisingly, the association of daptomycin and rifampin was less efficient than 
cloxacillin-rifampicin (- 1.76 log10 CFU/cm
2 (CI 95%: 0.61 to 2.9); P < 0.01) or vancomycin-
rifampicin (- 2.17 log10 CFU/cm
2 (CI 95%: 1.1 to 3.25); P < 0.001), for MSSA 27217. No 
emergence of antibiotic resistance was documented for any of the conditions tested. 
Spleen cultures were less often positive for MSSA than for MRSA, and no significant 
difference between the different conditions were noticed. 
 
Discussion 
The main findings of these experimental studies are: i) the results of the in vitro biofilm 
antibiotic susceptibility assays may vary according to the nature of the support used; ii) our 
mouse model of S. aureus vascular graft infection allowed us to test a large number of 
bacterial strains and antibiotic regimens and could pave the way toward a better 
understanding of antibiotic efficacy in PVGIs; iii) although more efficient than comparators 
for some bacterial strains, daptomycin was most of the time not superior to vancomycin or 
cloxacillin; and iv) combination of rifampicin and daptomycin did not enhance the 
bactericidal effect of daptomycin in this model.  
 
Decrease of antibiotic efficacy in material-related infections has been highlighted by many 
studies using biofilm susceptibility tests, including the Calgary device.8, 15, 20, 21 Although not 
recommended in routine,22 those techniques illustrate that MBICs and MBECs are much 
higher than MIC and MBC, with limited perspective of clinical cure since these 
concentrations are not achievable in humans.9, 21  However, those techniques use polystyrene 
devices, significantly different from biomaterials used for vascular prosthesis. Therefore, 
results yielded with those procedures may not be relevant for PVGIs.  We developed a model 
to evaluate specific MBICs and MBECs on Dacron®, referred as dMBICs and dMBECs, to 
better assess the decrease of antibiotics efficacy on bacteria embedded inside the biofilm on 
vascular prostheses. In this model, while dMIBCs and MBICs were comparable, dMBECs 
were lower than MBECs, although higher than MBCs. For instance, dMBICs and dMBECs of 
rifampicin were in the range of concentrations achievable in humans for most bacterial strains 
tested.  Biofilm developed onto plastic was more dense, and thicker, than the one found on 
Dacron® (figure 1), and adhesion of bacteria onto the Dacron® appeared weaker, explaining 
why antibiotics are less efficient in the polystyrene model. Our results demonstrated that 
classical techniques used to measure MBICs and MBECs could overestimate the decrease of 
antibiotic efficacy in the particular context of PVGIs, and that our model, specific to PVGIs, 
could yield more relevant findings. They do not question the recommendations of removing 
all infected material whenever possible for PVGI.23, 24 However, our data suggest that 
antibiotics alone may be a reasonable therapeutic option in selected cases when surgery would 
be associated with a high probability of severe adverse outcomes.25-27  
Animal models constitute a critical step for the evaluation of antibiotics for PVGIs. A rat 
model of PVGI using a Dacron® patch implanted in a dorsal subcutaneous pouch evaluated 
different prophylactic procedures.13, 28-30 Other models mimicked prosthetic-joint infections 
using a Teflon®-cage implanted in a dorsal subcutaneous pouch in Guinea-pigs,31-35 or rats.10 
To our knowledge, no specific model evaluated the curative treatment of PVGI so far. We 
combined two approaches to evaluate different antibiotic regimens in a PVGI mouse model. 
For technical reasons, it was impossible to implant our Dacron® along the vascular system, 
and this represents one weakness of our work. Some authors described rabbit,36 pig14 or dog11 
models of aortic graft infections, but those models do not allow the use of a large number of 
animals, and consequently are not appropriate for the screening of antibiotic strategies on 
different bacterial strains. Moreover, in a clinical setting, most PVGIs occur from the wound 
or from an adjacent infectious focus, and not through hematogenous route.37 Therefore, the 
infection process usually starts along the external part of the vascular prosthesis, not the 
endoluminal layer. Our model reproduces this pathway.  
Although all antibiotics tested in this model demonstrated efficacy when compared to 
controls, antibiotic efficacy varied according to bacterial strains. For instance, daptomycin 
was more bactericidal than vancomycin for MRSA BCB8 and MSSA 171, and more 
bactericidal than cloxacillin for MSSA 176, but this was not superior to other antibiotics for 
other strains. For MRSA BCB8, dMBIC and dMBEC were lower for daptomycin than for 
vancomycin and this could partially explain the differences noticed. One other explanation 
could be the different capabilities of antibiotics to penetrate the biofilm in vivo., although this 
would not explain the striking differences observed between strains.38 Daptomycin has 
already demonstrated better efficacy against MRSA than vancomycin in vitro39, 40 and in 
animal models.40, 41 This higher efficacy is thought to be linked to a better biofilm penetration 
for daptomycin than for vancomycin,42 and a better bactericidal activity against bacteria in 
stationary phase.40 However, some authors did not found any difference between daptomycin 
and vancomycin efficacy.43, 44 Our results highlight a possible differential activity of 
daptomycin according to the bacterial strain, that may explain the discrepancies between 
previous studies. 
Rifampicin has demonstrated its efficacy for the treatment of material-related staphylococcal 
infection45 and its use in combination is largely recommended. In the present study, we did 
not found any improvement of therapeutic efficacy when rifampicin was added to daptomycin 
for MRSA, but rifampicin enhanced the activity of vancomycin. The combination of 
daptomycin and rifampicin increased only moderately the bactericidal activity of daptomycin 
for MSSA 27217, while the addition of rifampicin to vancomycin or cloxacillin strongly 
enhanced their bactericidal effect for this strain. These results are in contrast with those of 
Sakoulas et al.,46 who demonstrated in a rat model of MRSA endocarditis a synergistic effect 
of daptomycin plus rifampicin. Saleh-Mghir et al. found similar results in a rabbit model of 
prosthetic joint infection.47 However, an in vitro pharmacodynamic model evaluating 
daptomycin and rifampicin against different MRSA strains found variable activity of this 
association (i.e. increased bactericidal activity with combinations in some, but not all strains 
tested.48 Likewise, the addition of rifampicin to daptomycin did not enhance the bactericidal 
activity of daptomycin in a rabbit model of MRSA endocarditis.49 Some studies suggested 
that daptomycin-fosfomycin or daptomycin-cloxacillin may be more synergistic.10, 50   
Our model could not capture the utility of combinations to prevent the emergence of 
resistance. Indeed, even when bacterial load was high after treatment, we did not document 
any bacterial resistance. This was unexpected, since emergence of resistance under treatment 
is one of the main caveats with rifampicin,41 or daptomycin monotherapies.41, 47 An 
experimental study evaluating the in vivo fitness of rifampicin-resistant S. aureus mutants in a 
mouse biofilm infection model found that rifampicin-resistant strains appeared after 3 to 9 
days of treatment.18 This delay may explain why our 48 h-treatment regimens were not 
associated with emergence of resistance. Thus, although no resistance was documented in our 
model, clinical data indicate that rifampicin must be used in combination for PVGI, as for any 
other infection. 
In conclusion, we found that biofilm formation and bacterial adhesion are weaker onto the 
Dacron® than onto polystyrene devices, resulting in a less pronounced biofilm-related 
decrease of antibiotic efficacy in the particular setting of PVGIs. We implemented an 
innovative mouse model of PVGI allowing the evaluation of a large number of antibiotic 
regimens. In this model, we demonstrated that daptomycin was more efficient than 
comparators for some strains but not all, and that the addition of rifampicin did not enhance 
daptomycin efficacy. However, due to the variability of findings according to bacterial 
strains, we were not able to determine the best antibiotic regimen for PVGIs. 
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    MSSA 27217      MRSA BCB8 
 Figure 1. Visualization of MSSA and MRSA 24h-biofilms on polystyrene (a) and on Dacron 
(b) using section views to observe biofilm thickness. All bacteria were stained green with 
Syto9®. The acquisition was performed on the whole biofilm thickness with an axial 
displacement of 1 µm. Images dimension is 82 x 82 µm². The scale bars correspond to 20 µm. 
Only biofilm for MSSA 27217 and MRSA BCB8 are represented since they were 
representative of all the biofilms visualized for other strains. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Results of bacterial count on Dacron patches and spleens after 48 h of treatment for 
MRSA infection. 
C: controls; V: vancomycin; D: daptomcyin; R: rifampicin; V-R: vancomycin-rifampicin; D-
R: daptomycin-rifampicin. CFU: Colony Forming Unit 
Stars represent results of comparison between control groups and each therapeutic group.  
* P < 0.05; ** P < 0.01; *** P < 0.001. § P < 0.001, comparison between vancomycin and  
daptomycin for MRSA BCB8. 
Number of mice per condition: 
 BCB8: n= 12 per antibiotic regimen 
 117: n= 10 per antibiotic regimen 
 33591: n= 14 per antibiotic regimen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Results of bacterial count on Dacron sheets and spleen after 48 h of treatment for 
MRSA infection. 
C: controls; V: vancomycin; D: daptomcyin; R: rifampicin; V-R: vancomycin-rifampicin; D-
R: daptomycin-rifampicin. CFU: Colony Forming Unit 
Stars represent results of comparison between control groups and each therapeutic group.  
* P < 0.05; *** P < 0.001.  P < 0.05, comparison between controls and daptomycin for MSSA 
176. ¤ P < 0.01, comparison between cloxacillin-rifampicin and daptomycin-rifampicin for 
MSSA 27217. # P < 0.001, comparison between vancomycin-rifampicin and daptomycin-
rifampicin for MSSA 27217 
Number of mice per condition: 
 171: n= 8 to 12 per antibiotic regimen 
 176: n= 10 to 15 per antibiotic regimen 
 27217: n= 12 to 15 per antibiotic regimen 
 
 
Table 1. In vitro drug-susceptibility testing for the bacterial strains used in this study  
 
Bacterial 
strains 
Antibiotic 
Classical methods  Biofilm on Dacron  Biofilm on polystyrene 
MIC MBC  dMBIC dMBEC  MBIC MBEC 
MRSA 
BCB8 
Vancomycin 1 1  1 > 32  1 > 256 
Daptomycin 0.125 0.125  0.5 8  1 > 256 
Rifampicin < 0.06 < 0.06  < 0.125 > 1  0,015 > 8 
117 
Vancomycin 1 4  4 16  1 > 256 
Daptomycin 1 2  2 64  1 > 256 
Rifampicin 0.015 0.03  0.015 > 0.5  0,015 > 8 
33591 
Vancomycin 1 2  4 16  2 > 256 
Daptomycin 0.25 0.5  2 > 16  1 > 256 
Rifampicin 0.0075 0.015  0.015 0.5  0,0075 > 8 
MSSA 
171 
Cloxacillin 0.25 0.5  2 > 32  0,25 > 256 
Vancomycin 1 1  8 32  4 > 256 
Daptomycin 0.5 0.5  4 > 32  4 > 256 
Rifampicin 0.015 0.03  0.125 > 0.25  0,015 > 8 
176 
Cloxacillin 0.5 0.5  2 > 32  0,5 > 256 
Vancomycin 1 1  2 16  1 > 256 
Daptomycin 0.5 0.5  2 > 64  0,5 > 256 
Rifampicin 0.015 0.03  0.125 > 0.5  0,015 > 8 
27217 
Cloxacillin 0.5 0.5  1 16  0,25 > 256 
Vancomycin 1 1  8 > 32  8 > 256 
Daptomycin 0.25 0.25  1 > 8  2 > 256 
Rifampicin < 0.06 0.125  2 2  0,03 > 8 
 
MIC: Minimum inhibitory concentration; MBC: minimum bactericidal concentration; dMBIC: Dacron-related minimal biofilm inhibitory 
concentration; dMBEC: Dacron-related minimal biofilm eradicating concentration; MBIC: minimal biofilm inhibitory concentration; MBEC: 
minimal biofilm eradicating concentration  
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